Anti-Lysyl tRNA synthetase antibody (ab31532)
- Product nameAnti-Lysyl tRNA synthetase antibodySee all Lysyl tRNA synthetase primary antibodies ...
- DescriptionRabbit polyclonal to Lysyl tRNA synthetase
- Tested applicationsICC/IF, IHC-P, IP, WB more details
- Species reactivityReacts with: Mouse, Human
Recombinant full length native protein (Human)
- Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.05% Sodium Azide
Constituents: Whole serum
- PurityWhole antiserum
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab31532 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||ICC/IF: Use at an assay dependent concentration. PubMed: 21460219|
|IHC-P||IHC-P: Use at an assay dependent dilution.|
|IP||IP: 1/3000 - 1/8000.|
|WB||WB: 1/8000. Predicted molecular weight: 74 kDa.|
- FunctionCatalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. When secreted, acts as a signaling molecule that induces immune response through the activation of monocyte/macrophages. Catalyzes the synthesis of diadenosine oligophosphate (Ap4A), a signaling molecule involved in the activation of MITF transcriptional activity. Interacts with HIV-1 virus GAG protein, facilitating the selective packaging of tRNA(3)(Lys), the primer for reverse transcription initiation.
- Involvement in diseaseDefects in KARS are the cause of Charcot-Marie-Tooth disease recessive intermediate type B (CMTRIB) [MIM:613641]; also called Charcot-Marie-Tooth neuropathy recessive intermediate B. CMTRIB is a form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.
- Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family.
- DomainThe N-terminal domain (1-65) of the cytoplasmic isoform is a functional tRNA-binding domain (By similarity), is required for nuclear localization, is involved in the interaction with DARS, but has a repulsive role in the binding to EEF1A1. A central domain (208-259) is involved in homodimerization and is required for interaction with HIV-1 GAG and incorporation into virions. The C-terminal domain (452-597) is not required for interaction with AIMP2.
- Cellular localizationMitochondrion and Cytoplasm. Nucleus. Cell membrane. Secreted. Secretion is induced by TNF-alpha.
- CMTRIB antibodyEC 126.96.36.199 antibodyKARS 1 antibody
- KARS 2 antibodyKARS antibodyKARS1 antibodyKARS2 antibodyKIAA0070 antibodyKRS antibodyLysine tRNA ligase antibodyLysine--tRNA ligase antibodyLysRS antibodyLysyl-tRNA synthetase antibodySYK_HUMAN antibody
Anti-Lysyl tRNA synthetase antibody images
ab31532 staining Lysyl tRNA synthetase in normal human breast tissue by Immunohistochemistry (paraffin embedded sections).
All lanes : Anti-Lysyl tRNA synthetase antibody (ab31532)
Lane 1 : HEK293 cell lysate
Lane 2 : A549 cell lysate
Lane 3 : HCC1208 cell lysate
Predicted band size : 74 kDa
Observed band size : 74 kDa
References for Anti-Lysyl tRNA synthetase antibody (ab31532)
This product has been referenced in:
- Gulati P et al. Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A 110:2557-62 (2013). WB, IP ; Mouse . Read more (PubMed: 23359686) »
- David A et al. RNA Binding Targets Aminoacyl-tRNA Synthetases to Translating Ribosomes. J Biol Chem 286:20688-700 (2011). WB, ICC/IF ; Human . Read more (PubMed: 21460219) »